Skip to main content
Premium Trial:

Request an Annual Quote

Health Canada Approves Two BCR-ABL Tests

NEW YORK (GenomeWeb) — Asuragen and MolecularMD announced today that Canadian regulators have approved their BCR-ABL tests for use in chronic myeloid leukemia (CML) patients.

According to Austin, Texas-based Asuragen, Health Canada has approved its qPCR-based QuantideX BCR-ABL IS kit. The test is designed to detect and quantify major breakpoint BCR-ABL1 fusion transcripts and is used to monitor molecular response in CML patients, regardless of tyrosine kinase inhibitor (TKI) therapy or disease management approach. The kit received US Food and Drug Administration premarket clearance in 2016 and CE marking in 2015. 

Meanwhile, MolecularMD said Health Canada has approved its PCR-based MRDx BCR-ABL test as an aid to monitor TKI treatment in Philadelphia chromosome positive CML patients, as well as for patients chronically treated with Novartis' Tasigna (nilotinib) who are candidates for discontinuation and monitoring of treatment-free remission. Patients in remission no longer taking Tasigna would continue to be monitored with MRDx BCR-ABL  — which is also FDA authorized and CE marked — to identify loss of molecular responses, MolecularMD noted.

Earlier this year, Portland, Oregon-based MolecularMD licensed the exclusive US marketing rights to the MRDx BCR-ABL test to Genoptix.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more